Exhibit 10.13.4
                                                                 ---------------















           CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF
            THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY
                          FILED WITH THE COMMISSION***





















                             CONFIDENTIAL TREATMENT

<PAGE>

                              DEVELOPMENT AGREEMENT
                              ---------------------

         THIS DEVELOPMENT  AGREEMENT (the  "Agreement") is made and entered into
as of the fourth _ day of March,  2003 (the  "Effective  Date"),  by and between
STIEFEL LABORATORIES, INC. ("Stiefel") and INyX PHARMA LIMITED ("INyX"). INyX is
a company organized under the laws of England and Wales with its principal place
of business at 6 Seymour Court, Manor Park,  Runcorn,  Cheshire WA7 1SY. Stiefel
is a New York  corporation  with its principal place of business at 255 Alhambra
Circle, Coral Gables, Florida 33134.

                                   BACKGROUND:

         Subject  to the  terms  and  conditions  contained  in this  Agreement,
Stiefel  desires  to  engage  INyX to  assist in  Stiefel's  development  of the
"Products"  (as   hereinafter   defined),   and  INyX  desires  to  accept  such
appointment.

         NOW,  THEREFORE,  FOR AND IN CONSIDERATION  of the premise,  the mutual
promises, covenants and agreements contained herein, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto hereby agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS
                                   -----------

         The following words,  terms and phrases,  when used herein,  shall have
the following respective meanings:

         1.1  "Batch"  shall mean the  quantity of cans as agreed  between  both
parties of the Products, produced pursuant to a single purchase order during the
same cycle of manufacture.

         1.2  "BioBatch"  shall mean a quantity of cans of the Products  that is
smaller than a Batch but not less than cans, whichever is greater.

         1.3  "cGMPs"  shall  mean  current  Good  Manufacturing  Practices,  as
published  at 21 CFR  parts  210 and 211 and  amended  during  the  term of this
Agreement.

         1.4 "FDA" shall mean the United States Food and Drug  Administration or
any successor agency thereof.

         1.5  "Health   Registrations"  shall  mean  the  Abbreviated  New  Drug
Application  approval  issued by the FDA with  respect to the  Products  and any
other governmental or regulatory consents,  registrations,  approvals or permits
necessary to sell or manufacture the Products or applications for the same.

         1.6 "Product" and "Products" shall mean ***.



___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

         1.7   "Specifications"   shall   mean   the   specifications   for  the
manufacturing,  packaging,  storage and  labeling of the  Products  described on
Exhibit  A  attached   hereto  and   incorporated   herein  by  reference.   The
Specifications  shall be automatically  amended upon each review and issuance of
the Health  Registrations  to include  the  information  set forth in the Health
Registrations.

         1.8 "Total  Development Cost" shall mean, with respect to each Product,
the amount designated as such on Exhibit B attached hereto.

                                    ARTICLE 2
                               RIGHTS TO PRODUCTS
                               ------------------

         2.1 For  greater  clarity,  INyX  acknowledges  that  all  intellectual
property created specifically in connection with the Products (the "Intellectual
Property"),  including  formulations,  inventions or discoveries  (first made or
reduced to practice in the performance of INyX's obligations hereunder) shall be
the property of Stiefel. INyX shall, when requested by Stiefel, execute all such
assignments,  consents  and other  documents  reasonably  necessary to assign to
Stiefel all right,  title and interest in and to all the Intellectual  Property,
and shall use best efforts to cause its employees,  agents and subcontractors to
execute the necessary documents to give effect to this provision.

         2.2 The  Customer  hereby  grants INyX a  royalty-free,  non-exclusive,
worldwide  right  and  license  to  make,  use and sell  products  incorporating
Intellectual Property, subject always to INyX's obligations hereunder.

                                    ARTICLE 3
                                   DEVELOPMENT
                                   -----------

         3.1 INyX agrees to assist  Stiefel in the  development of the Products,
as set forth in Exhibit B attached hereto.

         3.2 Stiefel agrees to reimburse INyX' efforts in the development of the
Products,  within  thirty (30) days of its receipt of invoices  from INyX.  With
respect to each Product, INyX agrees to timely complete all activities set forth
in Exhibit B attached  hereto in exchange for the respective  Total  Development
Cost set forth therein.

         3.3 INyX agrees to provide in a timely fashion all documents  requested
by Stiefel for submission in a Health Registration (including without limitation
those  documents  listed in Exhibit C attached  hereto) and to actually  support
Stiefel in responding to communications from the FDA.

         3.4  Stiefel and INyX  acknowledge  that INyX must  validate  three (3)
batches of the  Products  prior to selling any  Products to Stiefel.  INyX shall
complete such validation within sixteen (16) weeks of Stiefel's request. Stiefel
shall be obligated to purchase such Batches in accordance  with the terms of the
Manufacturing and Supply Agreement.


___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

                                    ARTICLE 4
                                   COMPLIANCE
                                   ----------

         4.1  Each  party  shall  promptly  deliver  to the  other a copy of all
written  communications  received  by it from  the FDA  during  the term of this
Agreement relating to the design, manufacture,  packaging,  shipping, storage or
sale of the  Products and allow the other party an  opportunity  to comment upon
its proposed response.

         4.2 Stiefel may perform  audits of INyX to establish  INyX'  compliance
with  cGMPs and the  Health  Registrations  or  regarding  other  manufacturing,
quality or regulatory  matters  affecting the Products,  with  reasonable  prior
notice.

         4.3 INyX shall immediately  notify Stiefel of any FDA inspections which
may affect any or all of the  Products,  allow Stiefel to be available to answer
FDA questions, and keep Stiefel informed to the maximum practicable extent as to
the inspection's progress.

         4.4 INyX agrees to provide to Stiefel, promptly upon Stiefel's request,
duly  authenticated  copies of all documents required to obtain and maintain the
Health  Registrations  and all documents  related to manufacturing the Products,
including without limitation those documents listed in Exhibit C.

                                    ARTICLE 5
                            PRICES, TERMS OF PAYMENT
                            ------------------------

         5.1 Payment.  With respect to each Product:  (a) Stiefel shall pay INyX
an amount equal to fifty percent  (50%) of the Total  Development  Cost,  within
thirty  (30)  days  after  INyX'  duly  authorized   representative  signs  this
Agreement;  (b) Stiefel  shall pay INyX an amount equal to  twenty-five  percent
(25%) of the  Total  Development  Cost,  within  thirty  (30)  days  after  INyX
completes  the  development  work set forth in  Exhibit B attached  hereto  with
respect to such Product; and (c) Stiefel shall pay INyX the balance of its Total
Development  Cost within thirty (30) days of Stiefel's filing an Abbreviated New
Drug Application in its own name with respect thereto.

                                    ARTICLE 6
                              TERM AND TERMINATION
                              --------------------

         6.1 Term.  Unless earlier  terminated in accordance with the provisions
hereof,  the term of this  Agreement  shall  commence on the Effective  Date and
shall  thereafter  continue in effect until the third (3rd)  anniversary  of the
Effective Date.


___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

         6.2 Termination for Cause. Either party may terminate this Agreement on
written notice to the other party, effective immediately if:

                  (a) the other  party  commits a material  breach of any of its
         obligations  hereunder  which is not cured  within  ninety (90) days of
         written notice from the other party specifying the breach; or

                  (b) the other party is dissolved or  liquidated,  files or has
         filed against it a petition  under any  bankruptcy  or insolvency  law,
         makes an  assignment  to the benefit of its  creditors,  has a receiver
         appointed  for  all or  substantially  all of  its  property,  or has a
         petition  under any bankruptcy or insolvency law filed against it which
         is not dismissed within sixty (60) days.

Such  right  of  termination  shall  be  in  addition  to  any  other  remedy  a
non-defaulting  party  may have at law or in  equity  due to the  other  party's
breach of is obligations hereunder.

         6.3  Termination  for Market  Conditions.  At any time and from time to
time,  Stiefel may terminate  this  Agreement  with respect to any or all of the
Products on ninety (90) days prior written notice to INyX, provided that Stiefel
shall accept and pay for all  development  work  performed by INyX in accordance
with  Exhibit B  attached  hereto  prior to INyX'  receipt  of such  notice  and
reasonable shut-down costs,  provided that in no event shall Stiefel's liability
for any such costs, plus amounts paid by Stiefel prior to such notice exceed (a)
with respect to any Product,  such Product's Total  Development  Cost; or (b) in
the aggregate for all Products ***.

         6.4  Changed  Circumstances.  In the  event  that  the  market  for the
Products  materially  changes or either  party,  in good faith,  believes that a
material change in such party's  circumstances beyond their control has occurred
which materially affects its ability to perform its obligations pursuant to this
Agreement,  the parties hereto shall, in good faith,  negotiate towards mutually
acceptable  revisions to this  Agreement to address the impact of such  material
changes;  provided,  however, the terms of this Agreement shall continue in full
force and effect unless and until the parties hereto agree otherwise.

         6.5 Force  Majeure.  The  failure  of either of the  parties  hereto to
perform any obligation under this Agreement solely by reason of any cause beyond
its control  (and due to no fault of its own),  including,  without  limitation,
acts  of God,  acts  of  government,  riots,  wars,  strikes  and  accidents  in
transportation,  shall not be deemed to be a breach of this Agreement; provided,
however,  that the party so prevented from complying  herewith shall continue to
take all actions within its power, including payment of outstanding invoices, to
comply as fully as possible herewith.









___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

                                    ARTICLE 7
                          INDEMNIFICATION AND INSURANCE
                          -----------------------------

         7.1  Indemnification.  INyX hereby indemnifies and agrees to defend and
hold Stiefel  harmless from and against losses,  claims,  damages,  liabilities,
costs and expenses  (including,  without  limitation,  attorneys' fees and court
costs)  incurred by Stiefel as a result of any breach of this Agreement by INyX.
Stiefel hereby  indemnifies and agrees to defend and hold INyX harmless from and
against losses,  claims,  damages,  liabilities,  costs and expenses (including,
without  limitation,  attorneys'  fees and court  costs)  incurred  by INyX as a
result of any breach of this Agreement by Stiefel,  Stiefel's  storage,  sale or
distribution  of  the  Products,  or  any  Products  labeling,   Specifications,
instructions,  directions,  warnings, pamphlets or other information provided by
Stiefel that differs from those provided by INyX.

         7.2  Insurance.  Each party hereto shall  maintain  with a  financially
sound and  reputable  insurer,  from the date of the first  purchase of Products
through  the  remainder  of the term of this  Agreement,  comprehensive  general
liability insurance, including, without limitation, Products liability insurance
with   liability   limits   of   at   least   Five   Million   Pounds   Sterling
((pound)5,000,000) per occurrence and in the aggregate.  Each party hereto shall
also name the other  party as an  additional  insured  party on its  policy  and
provide the other party with such evidence thereof as is reasonably requested by
the other party from time to time.

                                    ARTICLE 8
                  WARRANTIES AND REPRESENTATIONS OF THE PARTIES
                  ---------------------------------------------

         8.1  Additional  Representations  and  Warranties of INyX.  INyX hereby
additionally represents and warrants to Stiefel the following:

                  (a) INyX is a corporation  duly organized and existing in good
         standing under the laws of England;

                  (b) There are no material  adverse  claims  pending or, to the
         best of INyX's  knowledge,  threatened  against INyX by any entity with
         respect to the Products;

                  (c)  INyX is  neither  a party to nor  otherwise  bound by any
         agreement or instrument  which prohibits or prevents it from performing
         its obligations under this Agreement; and

                  (d) INyX's  manufacturing,  packaging  and storage  facilities
         comply in all material respects with all applicable federal,  state and
         local laws, rules and regulations in the Territory.

                  (e) INyX will make no use of  Confidential  Information of ***
         under the  provisions  of the Amended and  Restated  Manufacturing  and
         Supply  Agreement  between *** and ***, in performing  its  obligations
         hereunder.



___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

         8.2  Additional  Representations  and  Warranties  of Stiefel.  Stiefel
hereby additionally represents and warrants to INyX the following:

                  (a) Stiefel is a corporation duly organized and existing under
         the laws of the State of New York.

                  (b) There are no material  adverse  claims  pending or, to the
         best of Stiefel's  knowledge,  threatened against Stiefel by any entity
         with respect to any of its Products or business; and

                  (c) Stiefel is neither a party to nor  otherwise  bound by any
         agreement or instrument  which prohibits or prevents it from performing
         its obligations under this Agreement.

                                    ARTICLE 9
                CONFIDENTIALITY AND NONSOLICITATION OF PERSONNEL
                ------------------------------------------------

         9.1  Confidentiality.  Each party hereto  acknowledges that it has been
and will be exposed to certain  "Confidential  Information"  and "Trade Secrets"
(both  as  hereinafter  defined)  of the  other  party  in  connection  with the
transactions  contemplated  by this Agreement and that its  unauthorized  use or
disclosure of such  information  or data could cause  immediate and  irreparable
harm to such other party. Accordingly, except to the extent that it is necessary
to use such information or data to perform its obligations under this Agreement,
neither  party shall,  without the express  prior  written  consent of the other
party,  redistribute,  market,  publish,  disclose  or  divulge to any person or
entity,  or use or modify for use,  directly or  indirectly,  in any way for any
person or entity: (a) any of the other party's  Confidential  Information during
the  term of this  Agreement  and for a period  of three  (3)  years  after  any
expiration or  termination of this  Agreement;  and (b) any of the other party's
Trade  Secrets at any time during  which such  information  constitutes  a trade
secret under  applicable law. For purposes  hereof,  "Confidential  Information"
shall mean all  competitively  sensitive,  non-public  information  (other  than
"Trade  Secrets")  of or  about a  party  which  is not  generally  known  by or
available to such party's  competitors,  and "Trade  Secrets"  shall mean "Trade
Secrets" as defined under applicable law.

         9.2 Nonsolicitation of Personnel.  Neither party hereto shall,  without
the prior written  consent to the other party,  either  directly or  indirectly,
alone or in conjunction  with any other person or entity,  solicit or attempt to
solicit any "key or material" employee,  consultant,  contractor or personnel of
such other party to terminate,  alter or lessen his or her affiliation with such
other  party at any time during the term of this  Agreement  and for a period of
one (1) year thereafter.








___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

                                   ARTICLE 10
                             ARBITRATION OF DISPUTES
                             -----------------------

         10.1 All  disputes  arising  out of or in  connection  with the present
contract  shall  be  finally  settled  under  the  Rules of  Arbitration  of the
International  Chamber  of  Commerce  by one or more  arbitrators  appointed  in
accordance  with the said  Rules,  in  effect  at the  time the  arbitration  is
commenced. Such arbitration shall be conducted in a mutually convenient location
within an approximately  equal geographic  distance between the addresses of the
parties in effect. The decision of the arbitrators,  which may include interest,
shall be final and binding on the parties hereto and may be entered and enforced
in any court of competent  jurisdiction by any party.  The arbitration  shall be
pursued and brought to conclusion as rapidly as possible.

                                   ARTICLE 11
                                     NOTICES
                                     -------

         11.1 Delivery. All notices, consents, requests and other communications
hereunder  shall be in writing and shall be sent by hand delivery,  by certified
or  registered  mail  (return-receipt  requested),  or by a recognized  national
overnight courier service as set forth below:

                  If to INyX:        INyX, Inc.
                                     Seymour Court
                                     Manor Park
                                     Runcorn, Cheshire WA7 1SY
                                     Attention:

                  If to Stiefel:     Stiefel Laboratories, Inc.
                                     6290 Route 145
                                     Oak Hill, New York 12460
                                     Attention:  Purchasing Department

                  With a copy to:    Stiefel Laboratories, Inc.
                                     255 Alhambra Circle
                                     Coral Gables, Florida 33143
                                     Attention: General Counsel

         11.2 Effective Time.  Notices delivered pursuant hereto shall be deemed
given:  (a) at the time  delivered,  if  personally  delivered;  (b) at the time
received,  if mailed;  and (c) one (1) business day after timely delivery to the
courier, if by overnight courier service.

         11.3  Changes.  Either  party  hereto may  change the  address to which
notice is to be sent by written notice to the other party in accordance with the
provisions of this Article 11.



___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

                                   ARTICLE 12
                                  MISCELLANEOUS
                                  -------------

         12.1  Severability.  If any  provision of this  Agreement is held to be
invalid, illegal or unenforceable,  the validity, legality and enforceability of
the remaining  provisions shall not in any way be affected or impaired,  and the
parties  shall  use  their  best  efforts  to  substitute  a  valid,  legal  and
enforceable  provision,  which, insofar as practical,  implements the purpose of
this Agreement.

         12.2  Counterparts.  This  Agreement  may be  executed  in one or  more
counterparts,  each of  which  shall be  deemed  an  original,  but all of which
together shall be deemed one and the same instrument.

         12.3 Governing Law. This Agreement shall be governed by, and any matter
or dispute  arising out of this  Agreement  shall be determined  by, the laws of
England.

         12.4  Headings;   Gender.   "Article,"  "Section"  and  other  headings
contained in this Agreement are for reference purposes only and shall not affect
in any  way the  meaning  or  interpretation  of this  Agreement.  All  personal
pronouns used in this Agreement shall include the other genders, whether used in
the  masculine,  feminine or neuter  gender,  and the singular shall include the
plural and vice versa, whenever and as often as may be appropriate.

         12.5 Entire Agreement.  This Agreement  represents the entire agreement
of the parties with respect to its subject matter. Any and all prior discussions
or agreements with respect hereto are merged into and superseded by the terms of
this Agreement. This Agreement may be modified or amended only in writing signed
by both parties which expressly refers to this Agreement and states an intention
to modify or amend it. No such  amendment or  modification  shall be effected by
use of any purchase order, acknowledgment, invoice or other form of either party
and in the event of conflict  between the terms of this  Agreement  and any such
form, the terms of this Agreement shall control.

         12.6  Notices.  Any notice or payment  required or permitted  hereunder
shall be in writing and sent by certified mail, overnight express, or personally
delivered, addressed to the party to receive the notice as set out above.

         12.7 No Assignment.  Neither party hereto may assign this Agreement, in
whole or in part,  without the prior  written  consent of the other party (which
consent  shall not be  unreasonably  withheld  or  delayed),  and any  attempted
assignment not in accordance  herewith shall be null and void and of no force or
effect;  provided  that Stiefel may assign its rights (but not its  obligations)
hereunder to any of its subsidiaries.

         12.8 Binding  Effect.  This  Agreement  shall be binding upon and shall
inure to the  benefit of the  parties  hereto and their  respective  successors,
heirs, representatives and permitted assigns.


___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT
<PAGE>


         12.9  Interpretation.  This  Agreement  was  fully  negotiated  by both
parties  hereto and shall not be construed  more strongly  against  either party
hereto  regardless of which party is  responsible  for its  preparation.  In the
event of a  conflict  or  inconsistency  between  the  Manufacturing  and Supply
Agreement between the parties and this Agreement,  the relevant provision of the
Manufacturing  and Supply  Agreement  shall be given  effect  over the  relevant
provision of this Agreement.

         12.10 No Consequential  Damages.  Neither party to this Agreement shall
have any liability to the other party for any  consequential or indirect damages
arising out of any breach of this Agreement, including, without limitation, loss
of profit, loss of use or business stoppage.

         12.11  Further  Assurances.  Upon the  reasonable  request of the other
party,  each  party  hereto  agrees  to take any and all  actions  necessary  or
appropriate to give effect to the terms set forth in this Agreement.

                            [Signature Page Follows]




























___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT
<PAGE>


         IN  WITNESS  WHEREOF,   the  parties  hereto  have  caused  their  duly
authorized  representatives  to execute  this  Agreement  as of the day and year
first above written.

                                   "INyX"

                                   INyX PHARMA LIMITED.


                                   By: /S/ Colin Hunter
                                       -----------------------------------------
                                       Director


                                   "Stiefel"

                                   STIEFEL LABORATORIES, INC.


                                   By: /S/ Tessie L. Brunker
                                       -----------------------------------------
                                       Title:  Vice President, CEO and Treasurer





























___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

                                    EXHIBIT A

                                 SPECIFICATIONS

                         TO BE PROVIDED BY STIEFEL LABS
































___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT
<PAGE>


                                    EXHIBIT B

                       SCHEDULE OF DEVELOPMENT ACTIVITIES

         I. Task Name: ***             Start Date             Finish Date

                                       ***


1.       Project definition and scope.

2.       Acquisition,   Testing,  and  Evaluation  of  drugs,  excipients,   and
         components as agreed by both parties.

3.       Formulation  and  manufacturing   process   assessments  to  facilitate
         production of the product by INyX.

4.       Assessment and assistance, as necessary, in the development of mutually
         acceptable test methods required to secure health registrations.

5.       Development and Exhibit batch preparation.

6.       Development and preparation of necessary clinical supplies.

7.       Assistance,  as necessary with mutually  agreed  testing  activities to
         support health registrations.

8.       Support in  preparation  and review of CMC  documentation  necessary to
         secure health registrations.

TOTAL DEVELOPMENT COST:    ***




















___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT
<PAGE>


II. Task Name: ***                      Start Date            Finish Date

                                        ***

1.       Project definition and scope.

2.       Acquisition,   Testing,  and  Evaluation  of  drugs,  excipients,   and
         components as agreed by both parties.

3.       Formulation  and  manufacturing   process   assessments  to  facilitate
         production of the product by INyX.

4.       Assessment and assistance, as necessary, in the development of mutually
         acceptable test methods required to secure health registrations.

5.       Development and Exhibit batch preparation.

6.       Development and preparation of necessary clinical supplies.

7.       Assistance,  as necessary with mutually  agreed  testing  activities to
         support health registrations.

8.       Support in  preparation  and review of CMC  documentation  necessary to
         secure health registrations.

TOTAL DEVELOPMENT COST:    ***























___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

III. Task Name:***                      Start Date             Finish Date

                                        ***

1.       Project definition and scope.

2.       Acquisition,   Testing,  and  Evaluation  of  drugs,  excipients,   and
         components as agreed by both parties.

3.       Formulation  and  manufacturing   process   assessments  to  facilitate
         production of the product by INyX.

4.       Assessment and assistance, as necessary, in the development of mutually
         acceptable test methods required to secure health registrations.

5.       Development and Exhibit batch preparation.

6.       Development and preparation of necessary clinical supplies.

7.       Assistance,  as necessary with mutually  agreed  testing  activities to
         support health registrations.

8.       Support in  preparation  and review of CMC  documentation  necessary to
         secure health registrations.

TOTAL DEVELOPMENT COST:    ***
























___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT

<PAGE>

                                    EXHIBIT C

                      DOCUMENTATION TO BE PROVIDED BY INyX

Documentation Required for the ANDA Submission:
-----------------------------------------------

o        cGMP Certification

o        Debarment Statement

o        Methods - Raw material and Products

o        Specifications (Raw material and Products) - these may be updated based
         upon stability data, FDAs comment, etc.

o        Packaging component tests, specifications, and methods.

o        Batch records  (manufacturing and packaging) for the exhibit batch with
         lab pages of testing performed and Certificates of Analysis ("COAs")

o        Proposed Commercial Manufacturing and Packaging Batch Records

o        COA, lab pages, and  manufacturer's  COA for the active  ingredient/raw
         materials

o        Stability   data/reports  -  accelerated  and  long  term  (updated  in
         accordance with the stability schedule)

o        Proposed Post Marketing Stability Protocol

o        Standard Operating Procedures (various)

o        Description of INyX facilities

o        Method Validation Package

Documentation Required for Production Batches
---------------------------------------------

o        Releases of Raw Materials

o        Manufacturing and Packaging Batch Records

o        In-Process and Finished Products Testing Results  (including COAs, Test
         Records, etc.)























___________________________
***Confidential material redacted and filed separately with the Commission

                             CONFIDENTIAL TREATMENT